Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease.
Several approved therapies for multicentric Castleman disease (MCD) cannot be uniformly applied due to intolerable side effects. There is also a high percentage of recurrence of this disease despite treatment. Rituximab may be effective in controlling MCD in a subset of patients. This paper includes a brief case report and an extensive review of previously published cases. We observed an aggravation of concomitant cutaneous Kaposi sarcoma, and hypothesize that rituximab could have exacerbated it.
Casquero
Angela
A
Barroso
Alicia
A
Fernández Guerrero
Manuel L
ML
Górgolas
Miguel
M
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005871:Castleman Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods; D012514:Sarcoma, Kaposi / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab